2
项与 半延胡索酸阿利吉仑/苯磺酸氨氯地平/氢氯噻嗪 相关的临床试验An Open-label, Multicenter Study to Evaluate the Efficacy and Safety of a 4 Week Therapy With the Single Pill (SPC) Combination of Aliskiren 300 mg / Amlodipine 10 mg in Hypertensive Patients Not Adequately Respond to an Uptitrated 4 Week Therapy With the SPC of Olmesartan 40 mg / Amlodipine 10 mg, With a Potential Extension if Patients Still Not Adequately Respond With a 4 Week Therapy With the SPC Aliskiren 300 mg / Amlodipine 10 mg / HCTZ 12,5 mg
This study will assess the efficacy and safety of the single pill combination of Aliskiren and Amlodipine in patients with moderate hypertension not adequately responding to a single pill combination of Olmesartan and Amlodipine.
Further this study will also assess the efficacy and safety of a single pill combination of Aliskiren, Amlodipine and Hydrochlorothiazide (HCTZ) in patients with moderate hypertension not adequately responding to a single pill combination of Aliskiren and Amlodipine.
Multi-center, Open Label, 18-week Study to Demonstrate the Efficacy and Safety of Combination Therapy of Aliskiren/Amlodipine or Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Stage II HT
This study assessed the efficacy and safety of combination therapy of Aliskiren/Amlodipine or Aliskiren/Amlodipine/Hydrochlorothiazide in patients with stage II Hypertension.
100 项与 半延胡索酸阿利吉仑/苯磺酸氨氯地平/氢氯噻嗪 相关的临床结果
100 项与 半延胡索酸阿利吉仑/苯磺酸氨氯地平/氢氯噻嗪 相关的转化医学
100 项与 半延胡索酸阿利吉仑/苯磺酸氨氯地平/氢氯噻嗪 相关的专利(医药)
100 项与 半延胡索酸阿利吉仑/苯磺酸氨氯地平/氢氯噻嗪 相关的药物交易